BioMedNewsBreaks

FridayFeb 19, 2021 10:42 am

BioMedNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Announces $11.7M Private Placement

180 Life Sciences (NASDAQ: ATNF), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, today announced its entry into securities purchase agreements with certain institutional investors to raise approximately $11.7 million through the private placement of 2,564,000 shares of its common stock and accompanying warrants to purchase an aggregate of up to 2,564,000 shares of common stock at a combined purchase price of $4.55 per share and accompanying warrant. The warrants will be immediately exercisable at an exercise price of $5.00 per share and will expire five years…

Continue Reading

FridayFeb 19, 2021 10:03 am

BioMedNewsBreaks – DarioHealth Corp. (NASDAQ: DRIO) CEO Slated to Host Investor Meetings at Global Healthcare Conference

DarioHealth (NASDAQ: DRIO), a pioneer in the global digital therapeutics market, has announced that CEO Erez Raphael will be participating in the upcoming SVB Leerink Global Healthcare Conference. The 10th annual SVB Leerink Healthcare Conference will be held Feb. 24–26, 2021. Raphael will participate in the  premiere event and is also scheduled to host investor meetings during the three-day virtual gathering. DarioHealth is recognized for providing one of the highest-rated diabetes and hypertension solutions available today with a team of experts that have impressive experience in the life sciences, behavioral science and software technology sectors. The company is covering new…

Continue Reading

ThursdayFeb 18, 2021 2:47 pm

BioMedNewsBreaks – Lincoln Health Network’s Upcoming Conference to Showcase Latest Innovations, Cover Every Facet of Clinical Doc Management

Lincoln Health Network, a renowned conference production company dedicated to shining a spotlight on the latest technologies and trends within the pharmaceutical, medical devices and biotech fields, today announced its plans to host the upcoming Clinical Document World conference. The event is set to take place in an entirely digital format on Feb. 24-26, 2021. The summit is designed to operate as a one-stop learning experience for life sciences professionals seeking to improve upon their clinical documentation process and will provide attendees with three days of sessions featuring faculty experienced in clinical documentation, trial master files, inspection readiness, risk management…

Continue Reading

ThursdayFeb 18, 2021 12:53 pm

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces Key Milestone, Progress Toward Collaborative Clinical Trials

CNS Pharmaceuticals (NASDAQ: CNSP) and WPD Pharmaceuticals (CSE: WBIO) (8SV1.F) (“WPD”), biopharmaceutical companies specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, today announced that WPD received a positive opinion of the Lower Silesian Medical Chamber Ethics Committee in Wrocław, Poland for its planned upcoming Berubicin clinical trial in adults with Glioblastoma Multiforme (“GBM”) under the WPD-201 Clinical Trial Protocol. CNS Pharmaceuticals has received study level approval from the Central IRB for the CNS-201 Clinical Trial Protocol. Berubicin is the company’s novel anthracycline candidate for the treatment of a number…

Continue Reading

ThursdayFeb 18, 2021 11:58 am

BioMedNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Announces $17.6M Private Placement

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announced its entry into securities purchase agreements with certain institutional and accredited investors to raise approximately $17.6 million through the issuance of an aggregate of 9,043,766 shares of its common stock and warrants to purchase up to an aggregate of 4,521,883 shares of common stock, at a purchase price of $1.95 per share of common stock and associated warrant. The private placement is priced at-the-market under Nasdaq rules. Subject to the satisfaction of customary conditions, the closing of the private…

Continue Reading

WednesdayFeb 17, 2021 12:16 pm

BioMedNewsBreaks – Brain Scientific Inc. (BRSF) Signs Memorandum of Understanding with Ehave, Inc. (EHVVF) to Map Brain Response

Brain Scientific (OTCQB: BRSF), a commercial-stage, health-care company with two FDA-cleared products, has entered into a memorandum of understanding (“MoU”) with Ehave, Inc. (OTC: EHVVF), a provider of digital therapeutics for the psychedelic and mental health sectors. The agreement calls for the two companies to work together to map brain response to psychedelics being administered as a treatment for chronic pain, depressions (both major and persistent), post-traumatic stress disorder, bipolar disorder, general anxiety, ADHD and schizophrenia. The two companies will also collaborate in the development of neural net algorithms for the mental-health sector. BRSF’s e-tattoo technology will be used to provide…

Continue Reading

WednesdayFeb 17, 2021 10:50 am

BioMedNewsBreaks – Predictive Oncology (NASDAQ: POAI) Closes on $7.4M Registered Direct Offering, Announces Breakthrough Discoveries

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, announced that it had closed on its previously announced registered direct offering. The offering, comprised of 4,222,288 shares of POAI common stock sold at $1.75 per share, totaled $7.4 million in gross proceeds for the company, before expenses were deducted. The shares were priced at-the-market under Nasdaq rules. The announcement also noted that the company issued a concurrent private placement to the same investors; that placement comprised of unregistered warrants up 2,111,144 shares of common stock, priced at $2 per share.…

Continue Reading

WednesdayFeb 17, 2021 10:30 am

BioMedNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Executes Purchase Agreement to Raise $10.2M

Processa Pharmaceuticals Inc. (NASDAQ: PCSA), a clinical-stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have unmet medical needs, has executed a securities purchase agreement. The agreement is intended to raise gross proceeds of $10.2 million through the sale of 1,321,132 shares. The shares will be sold at $7.75 per share through a private investment in public equity (“PIPE”) financing. In the announcement, the company reported that the financing attracted both institutional and accredited investors, with the private placement closing expected on or about Feb. 23, 2021. “We believe these additional resources position…

Continue Reading

TuesdayFeb 16, 2021 2:03 pm

BioMedNewsBreaks – Artelo Biosciences Inc. (NASDAQ: ARTL) Appoints Senior Pharmaceutical Exec as New SVP, Chief Scientific Officer

Artelo Biosciences (NASDAQ: ARTL), a clinical stage biopharmaceutical company focused on the development of therapeutics that modulate endogenous signaling pathways including the endocannabinoid system, today announced the appointment of Andrew Yates, Ph.D, as senior vice president and chief scientific officer. Dr. Yates is an experienced senior pharmaceutical executive, having most recently served at AstraZeneca in significant roles across a number of functional areas including development and commercial strategy, medical affairs and business development. Notably, Dr. Yates has been extensively involved in the life-cycle management of key multi-billion-dollar products including CRESTOR(R), FORXIGA(R) and KEYTRUDA(R). “We are extremely pleased to announce the…

Continue Reading

TuesdayFeb 16, 2021 11:05 am

BioMedNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Announces Completion of European CE-IVD Application for 25-Minute COVID-19 RT-PCR Test

XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) has made a significant announcement, along with its exclusive German diagnostics development partner, 3a-diagnostics GmbH ("3a"). The companies have completed all actions and procedures required for the European regulatory application for the rapid point-of-care SARS-CoV-2 (COVID-19) RT-PCR Test System. The announcement noted that ISO 13485 approval for 3a as a medical device manufacturer is expected in the next few weeks; 3a also anticipates European regulatory approval as a commercial in vitro diagnostic device (CE-IVD) for COVID-ID Lab by early March. The exclusive lab is designed to be a rapid, accurate and robust test…

Continue Reading